Skip to main content
. 2022 Aug;63(8):1223–1230. doi: 10.2967/jnumed.121.262992

TABLE 2.

Characterization of 225Ac-Labeled HER2-Targeting Trastuzumab

Radiolabeling efficiency (%) Immunoreactivity (%) Specific activity* (MBq/mg of antibody) Radiochemical purity 24-h retention (%) KD (nM)
BT474 BT474_R
53.8 ± 11.4 (n = 14) 95.9 ± 1.4 (n = 14) 3.4 ± 0.7 (n = 11) 97.8 ± 1.8 (n = 14) 90.6 ± 2.5 (n = 14) 24.6 ± 4.9 10.2 ± 1.7

*Starting activity, 0.4–1.1 MBq

KD = dissociation constant.